Japan's Nichi-Iko prepping for US biosimilar entry
This article was originally published in Scrip
Executive Summary
The major Japanese generics firm Nichi-Iko has signalled its intention to move into the biosimilars sector in the US through the establishment of a new subsidiary in this market.
You may also be interested in...
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.